Last reviewed · How we verify
Pharmacological
Pharmacological is a Small molecule drug developed by University of Virginia. It is currently in Phase 1 development.
Pregnenolone is being studied in clinical trials for various conditions, including Pulmonary Arterial Hypertension, Major Depressive Disorder, Advanced Bile Duct Carcinoma, Stage II Esophageal Cancer, Stage II Pancreatic Cancer, and is being administered in doses of 500 mg and 800 mg. Kettlebell Exercise is also being studied as an intervention in a clinical trial for Pulmonary Arterial Hypertension.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Pharmacological |
|---|---|
| Sponsor | University of Virginia |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma (PHASE1)
- A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) (PHASE3)
- Menopausal Hormones and Sympathetic Activation (PHASE4)
- Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma (PHASE2)
- Induction of Labor by Cervical Ripening and Transcutaneous Electrical Nerve Stimulation (TENS) (NA)
- Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma (PHASE1)
- Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas (PHASE1)
- A Screening Program to Improve the Early Detection of Sporadic Pancreatic Cancer in Individuals With a High-Risk of Developing Pancreatic Cancer (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pharmacological CI brief — competitive landscape report
- Pharmacological updates RSS · CI watch RSS
- University of Virginia portfolio CI
Frequently asked questions about Pharmacological
What is Pharmacological?
Who makes Pharmacological?
What development phase is Pharmacological in?
Related
- Manufacturer: University of Virginia — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing